Related Experiment Video
Updated: May 6, 2026
08:45
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
13.2K
Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia
Juyi Li1, Xiufang Wang, Zhaoqing Zhang
1The Third Hospital of Wuhan , Wuhan, Hubei Province , China.
Current Medical Research and Opinion
|October 26, 2013
Summary
The CYP2D6*10 (C188T) gene polymorphism is common in the Ningxia Hui population but not linked to hyperlipidemia. However, the CC genotype may enhance simvastatin
Area of Science:
- Pharmacogenomics
- Genetics
- Cardiovascular Disease Research
Background:
- The CYP2D6 gene plays a role in drug metabolism, influencing statin efficacy.
- Genetic variations like CYP2D6*10 (C188T) can impact drug response and disease susceptibility.
- Hyperlipidemia is a major risk factor for cardiovascular diseases, necessitating effective treatment strategies.
Purpose of the Study:
- To determine the frequency of the CYP2D6*10 (C188T) gene polymorphism in the Ningxia Hui population.
- To investigate the association between CYP2D6*10 (C188T) polymorphism and hyperlipidemia.
- To evaluate the influence of CYP2D6*10 (C188T) polymorphism on the lipid-lowering efficacy of simvastatin.
Main Methods:
- Genotyping for CYP2D6*10 (C188T) using allele-specific amplification (ASA-PCR).
- Recruitment of 150 healthy individuals and 200 hyperlipidemia patients from Ningxia People's Hospital.
- Analysis of genotype-lipid level correlations and simvastatin's lipid-lowering effects.
Main Results:
- The CYP2D6*10 allele frequency was 47.6% in the Ningxia Hui population.
- No significant correlation was found between CYP2D6*10 allele and hyperlipidemia.
- Simvastatin treatment led to greater reductions in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in patients with the CC genotype compared to CT and TT genotypes.
Conclusions:
- CYP2D6*10 gene polymorphism distribution varies ethnically and geographically.
- The T allele of CYP2D6*10 is not associated with hyperlipidemia.
- The CC genotype appears to enhance simvastatin's lipid-lowering effects, suggesting potential dose adjustments for hyperlipidemia patients in the Ningxia Hui population.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
350
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
350
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
01:27Pharmacogenetics of Drug Metabolism: Overview
196
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
196
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84